This is to provide you with important information regarding Antivenin (Micrurus fulvius) (Equine), commonly referred to as North American Coral Snake Antivenin. Antivenin (Micrurus fulvius) (Equine) is indicated for treatment of envenomation by Micrurus fulvius fulvius (Eastern Coral Snake) and Micrurus fulvius tenere (Texas Coral Snake). This product was manufactured by Wyeth Pharmaceuticals, now a wholly owned subsidiary of Pfizer, Inc.
FDA has extended the expiration date on this lot of Antivenin (Micrurus fulvius) (Equine). The extension is based upon FDA evaluation of stability data, which determined that this lot of product will maintain stability and potency for an additional year.
Wyeth Pharmaceuticals no longer manufactures Antivenin (Micrurus fulvius) (Equine). There is no alternative product licensed in the
Lot 4030026 continues to be available. Wyeth is closely managing their inventory, and will supply product only to direct customers.
Information for Health Care Professionals: Anticipated Short Supply of Coral Snake Antivenom (Pfizer Inc. )[ARCHIVED] North American Coral Snake Antivenin (Micrurus fulvius) (Equine) Lot 4030026 - Dear Health Care Provider Letter(PDF - 19KB) Package Insert - North American Coral Snake Antivenin(PDF - 70KB)